PRO-C12
A fragment of the C-terminal domain of type XII collagen, enabling non-invasive monitoring of cancer-associated fibroblast (CAFs) activity and extracellular matrix remodeling in solid tumors.
Key features and values
- Quantifies type XII collagen fragments associated with extracellular matrix remodeling.
- Reflects cancer-associated fibroblast activity in the tumor microenvironment.
- Provides a non-invasive measure of extracellular matrix dynamics in oncology research.
- Supports monitoring of disease progression and response to therapies targeting tumor stroma.
- Applicable in research on solid tumors characterized by aberrant extracellular matrix turnover.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation in cancer.
- Complements other biomarkers for a comprehensive assessment of tumor microenvironment dynamics.
Description
The PRO-C12 biomarker assay measures specific fragments of the C-terminal domain of type XII collagen, serving as an indicator of cancer-associated fibroblast activity and extracellular matrix remodeling in solid tumors. This non-invasive assay provides insights into tissue remodeling processes associated with cancer progression. By quantifying type XII collagen degradation products, the PRO-C12 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tumor stroma remodeling. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover in oncology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
